Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide curative therapy for acute lymphoblastic leukaemia in children

Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide... Minimal residual disease (MRD) is of high prognostic value in risk stratification in childhood acute lymphoblastic leukaemia. Flow cytometry (FCM) was shown to yield reliable results in MRD measurement. However, the interpretation of FCM data relies largely on operator skills and experience. While sample preparation, antibody panels, staining procedures and flow cytometric acquisition can be standardized, easily controlled and be made available worldwide, the availability of experienced operators represents the current bottleneck to a growing number of laboratories to the benefit of an increasing number of patients with leukaemia. Currently, international paediatric studies—throughout Europe, South America, to Australia—aim at stratifying the treatment according to the FCM-MRD methodology. The measurements are still operator-dependent leading to substantial costs regarding training and quality control. This article introduces a new European Union-funded project (AutoFLOW) aiming at the standardization and automation of FCM-MRD analysis by machine-learning technology. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide curative therapy for acute lymphoblastic leukaemia in children

Loading next page...
 
/lp/springer-journals/towards-automation-of-flow-cytometric-analysis-for-quality-assured-4p6WP1GzaM

References (24)

Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0172-6
Publisher site
See Article on Publisher Site

Abstract

Minimal residual disease (MRD) is of high prognostic value in risk stratification in childhood acute lymphoblastic leukaemia. Flow cytometry (FCM) was shown to yield reliable results in MRD measurement. However, the interpretation of FCM data relies largely on operator skills and experience. While sample preparation, antibody panels, staining procedures and flow cytometric acquisition can be standardized, easily controlled and be made available worldwide, the availability of experienced operators represents the current bottleneck to a growing number of laboratories to the benefit of an increasing number of patients with leukaemia. Currently, international paediatric studies—throughout Europe, South America, to Australia—aim at stratifying the treatment according to the FCM-MRD methodology. The measurements are still operator-dependent leading to substantial costs regarding training and quality control. This article introduces a new European Union-funded project (AutoFLOW) aiming at the standardization and automation of FCM-MRD analysis by machine-learning technology.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Sep 11, 2014

There are no references for this article.